Trial Profile
To estimate the occurrence of dose increase beyond labelled dose of biologics (adalimumab,infliximab,ustekinumab,etanercept) in patients with moderate to severe Psoriasis : A real world study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 09 Jun 2017 New trial record